Sakamoto, C
Kohara, H
Inoue, H
Narusawa, M
Ogawa, Y
Hirose-Yotsuya, L
Miyamoto, S
Matsumura, Y
Yamada, K
Takahashi, A
Tani, K
Article History
Received: 21 July 2016
Revised: 21 November 2016
Accepted: 22 November 2016
First Online: 13 January 2017
Competing interests
: KT receives research funding from SBI Pharmaceutical and Shinnihonseiyaku to develop novel cancer therapies. The terms of this arrangement have been reviewed and approved by the University of Tokyo in accordance with its conflict of interest policies. The other authors declare no conflict of interest.